BioPlx raises $1.64M in first funding round
BOULDER — BioPlx Inc., a company producing treatments to prevent recurring staph infections, has closed on a $1,641,415 fundraising round Monday morning.
The Boulder-based biotreatment company raised the funds from 12 investors in an all-equity offering after opening the round in mid-June, according to filings with the U.S. Securities and Exchange Commission.
It was the company’s first fundraising round recorded with the SEC.
SPONSORED CONTENT
Business Cares: April 2024
In Colorado, 1 in 3 women, 1 in 3 men and 1 in 2 transgender individuals will experience an attempted or completed sexual assault in their lifetime. During April, we recognize Sexual Assault Awareness Month with the hopes of increasing conversations about this very important issue.
BioPlx’s main focus is developing non-antibiotic treatments for strains of MRSA, a type of staph infection that is increasingly resistant to traditional antibiotics. The U.S. Centers for Disease Control estimates that at least two million people per year contract some form of antibiotic-resistant bacteria and 23,000 people die from it.
BOULDER — BioPlx Inc., a company producing treatments to prevent recurring staph infections, has closed on a $1,641,415 fundraising round Monday morning.
The Boulder-based biotreatment company raised the funds from 12 investors in an all-equity offering after opening the round in mid-June, according to filings with the U.S. Securities and Exchange Commission.
It was the company’s first fundraising round recorded with the SEC.
BioPlx’s main focus is developing non-antibiotic treatments for strains of MRSA, a type of staph infection that is increasingly resistant to traditional antibiotics. The U.S. Centers for Disease Control estimates that at least two million people per year contract…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
